Paper Details

  1. Home
  2. Paper Details

Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.

Author: GotfriedMark, JivcuCristian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Gemifloxacin, a fluoroquinolone, is effective against bacteria associated with acute exacerbation of chronic bronchitis (AECB). Gemifloxacin has a lower minimal inhibitory concentration (MIC) against Streptococcus pneumoniae than other respiratory fluoroquinolones and activity against bacterial DNA gyrase and topoisomerase IV, potentially decreasing resistance. Clinically, gemifloxacin has been shown to shorten hospital stays and improve long-term outcomes in AECB patients. While gemifloxacin is generally well-tolerated, the most common side effects include rash and gastrointestinal upset.
Paper Details　
Original Abstract of the Article :
The newest generation of fluoroquinolones have proven efficacy against bacterial organisms associated with acute exacerbation of chronic bronchitis (AECB). Gemifloxacin, as one of the quinolones in this class, exhibits many of the pharmacokinetic and pharmacodynamic characteristics of the class with...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722869/

データ提供：米国国立医学図書館（NLM）

Gemifloxacin: A Potential Treatment for Acute Bacterial Exacerbation of Chronic Bronchitis

This study investigates the effectiveness of gemifloxacin, a fluoroquinolone antibiotic, in treating acute bacterial exacerbation of chronic bronchitis (AECB), highlighting its potential as a treatment option for this common and debilitating condition. It's like exploring a vast desert landscape of respiratory ailments, seeking effective solutions for those suffering from AECB.

Gemifloxacin's Potential: A Oasis of Relief

The study reveals that gemifloxacin exhibits significant efficacy against bacterial organisms associated with AECB, offering a potential path toward improved outcomes for patients. It's like finding a hidden spring in the desert, providing much-needed relief from the symptoms of AECB.

A New Weapon in the Fight Against Bronchitis: Navigating the Desert of Respiratory Illnesses

The research suggests that gemifloxacin could be a valuable tool in the treatment of AECB, providing an effective option for managing this challenging condition. It's like acquiring a new weapon in the fight against respiratory illnesses, equipping us with the tools to overcome the challenges posed by AECB.

Dr. Camel's Conclusion

This study provides encouraging evidence for the effectiveness of gemifloxacin in treating AECB. It's like discovering a new oasis in the desert of respiratory ailments, offering hope for those seeking relief from this debilitating condition. While further research is needed to fully understand its long-term efficacy and safety, gemifloxacin represents a promising avenue for managing AECB and improving patient outcomes.
Date :
  1. Date Completed 2010-02-04
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

19684863

DOI: Digital Object Identifier

PMC2722869

Related Literature

Article Analysis
・Side Effects of gemifloxacin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.